{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:27:39Z","timestamp":1783625259188,"version":"3.55.0"},"reference-count":95,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Comorbid obesity, dyslipidemia, and hypertension place patients with type 2 diabetes (<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>) at greatly increased risk of cardiovascular (<jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>) disease\u2010related morbidity and mortality. An urgent need exists for effective treatment for patients with <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> that encompasses glycemic control, weight loss, and reduction in <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> risk factors. The glucagon\u2010like peptide\u20101 receptor agonists (<jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>s) liraglutide and exenatide are incretin\u2010based antidiabetes agents. This review examines <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>\u2010associated effects of liraglutide and exenatide in animal models and clinical trials with patients with <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>. Studies support the effectiveness of <jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>s in reducing hyperglycemia. Further, <jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>s represent a significant advance in <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> treatment because they uniquely affect a broad array of <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> risk factors through significant weight and systolic blood pressure reduction, improved lipid levels, and possibly, as shown in <jats:italic>in vitro<\/jats:italic> studies and animal models, through direct effects on cardiac myocytes and endothelium.<\/jats:p>","DOI":"10.1111\/1755-5922.12000","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T02:08:16Z","timestamp":1374199696000},"page":"238-249","source":"Crossref","is-referenced-by-count":63,"title":["<scp>GLP<\/scp>\u20101 Receptor Agonists: Effects on Cardiovascular Risk Reduction"],"prefix":"10.1111","volume":"31","author":[{"given":"Daniel","family":"Lorber","sequence":"first","affiliation":[{"name":"Division of Endocrinology New York Hospital Queens Flushing NY USA"},{"name":"Department of Medicine Weill Medical College of Cornell University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.179294"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1190-x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2124"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.412"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191259"},{"issue":"1","key":"e_1_2_7_9_1","first-page":"S11","article-title":"Standards of medical care in diabetes\u20132012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1157-y"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.6.540"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.03.012"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.739938"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1193"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.206425"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.12.075"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139339.85840.DD"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2009.03.016"},{"key":"e_1_2_7_21_1","first-page":"A10278","article-title":"Incretin\u2010based treatments prevent the development of atherosclerotic lesions in apolipoprotein e\u2010null mice [abstract]","volume":"122","author":"Watanabe T","year":"2010","journal-title":"Circulation"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00012"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.05.022"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2006.08.211"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00237.2004"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1949"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2011-1052"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9909645"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.5.1187"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2375"},{"key":"e_1_2_7_31_1","volume-title":"Bydureon\u2122 (exenatide extended\u2010release for injectable suspension) [prescribing information]","author":"Amylin Pharmaceuticals Inc","year":"2012"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1355"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2124"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1472-y"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2081"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2361"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01154.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1521"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2009.0141"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253870"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.08.006"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.04.022"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2011.149"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1831-8"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.12.039"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-08-0468"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2011.11.008"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2009.07.003"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1694"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.12.131"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164109360269"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.01.003"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-010-0559-9"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/met.2008.0095"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-9-76"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-9-32"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.033"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-9-31"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0685"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-11-0015"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111404257"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2003.11.001"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215595"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.222653"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1393"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-22"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2440-x"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61303-8"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2009.245"},{"key":"e_1_2_7_77_1","unstructured":"FonsecaV DeVriesJH BainSC et\u00a0al.Liraglutide improves the profile of lipid and cardiovascular risk biomarkers from baseline. Presented at: 21st World Diabetes Congress of the International Diabetes Federation; December 4\u20138 2011;Dubai United Arab Emirates."},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02656.x"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.05.028"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.04.024"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02484.x"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1961"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2001.138"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2003.10719316"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-008-0023-0"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01356.x"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03301.x"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01428.x"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.09.002"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.03.015"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2009.05.1998"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111408937"},{"key":"e_1_2_7_93_1","first-page":"A612","article-title":"Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER\u2122) Trial: Rationale and study design [abstract]","volume":"60","author":"Bergenstal R","year":"2011","journal-title":"Diabetes"},{"key":"e_1_2_7_94_1","unstructured":"ClinicalTrials.gov.Exenatide study of cardiovascular event lowering trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available from:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01144338[accessed 9 April 2012]."},{"key":"e_1_2_7_95_1","unstructured":"ClinicalTrials.gov.Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results \u2013 a long term evaluation (LEADER). Available from:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01179048[accessed 9 April 2012]."},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2260"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12000","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1755-5922.12000","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:49:42Z","timestamp":1696326582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/1755-5922.12000"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12000","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]}}}